MYC (V-myc avian myelocytomatosis viral oncogene homolog)

Methods Male BALB/c mice were randomly divided into 6 groups: normal group, model group, Euphorbia helioscopia water extract low-, medium-, and high-dose groups (0.9, 1.8, 3.6 g/kg), and aspirin group (20 mg/kg)...The protein expression levels of programmed death ligand 1 (PD-L1), cluster of differentiation 47 (CD47), phosphorylated nuclear factor κB p65 subunit (p-NF-κB p65), and phosphorylated signal transducer and activator of transcription 3 (p-STAT3) were decreased. Conclusion The aqueous extract of Euphorbia helioscopia L. can effectively inhibit LPS/NNK-induced formation of lung adenoma nodules by improving the immune environment, and its mechanism may involve regulating the activation of NF-κB and STAT3.

Further analyses of cocultured MB cells revealed a myogenic differentiation program enriched in MYC-driven MB and recurrent disease, which is associated with poorer prognosis. Together, this work establishes a collection of CbO models for studying group 3/4 MB initiation, growth, and microenvironmental dependencies and provides a tractable platform for further mechanistic and therapeutic investigation of these tumors.

ZGMD achieved a signal-to-background ratio (SBR) of 291 for endogenous c-MYC by ARET bioimaging in vivo, and the afterglow signal of ZGMD was observed within 6 min in mice after preirradiation, which unlocked spatiotemporal dynamics of dual-modal bioimaging. Importantly, the ZGMD nanoplatform could visualize the dynamic fluctuations of endogenous c-MYC within tumors by dual-modal spatiotemporal bioimaging, providing a noninvasive tool for real-time assessment in disease diagnosis and cancer therapy.

P=N/A, N=40, Chongqing University Cancer Hospital; Chongqing University Cancer Hospital

MYC/BCL2 double-expressor lymphoma (DEL), a distinct population of DLBCL defined by MYC and BCL2 coexpression, refers to poor prognosis after standard rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) immunochemotherapy. This trial is the first to demonstrate the benefit of an epigenetic modulator in DLBCL, offering a new first-line therapeutic approach dually targeting MYC and BCL2 oncoprotein for this high-risk population. ClinicalTrials.gov Identifier: NCT04231448.

This work highlight the complexity of the disease and provide new insight into the utility of prognostic biomarkers and potential druggable targets for future study.

NeuroD1 and BRD4 interacted with each other and bind to ecMYC E1, looping the enhancer to the MYC promoter. Together, these findings define a mechanism that regulates amplified MYC gene expression within ecDNA or HSRs specifically in G3-MB.

Multiparameter optimization yielded compound 18, which demonstrated improved efficacy in a MYC-dependent Burkitt lymphoma xenograft model at a significantly lower dose than the RUVBL1/2 inhibitor CB-6644. This work establishes SMT as a powerful tool to facilitate the drug discovery SAR campaigns and evaluates the therapeutic potential of RUVBL1/2 inhibition in MYC-dependent cancers.

Moxibustion can enhance the anti-tumor effect of Trametinib by inhibiting the phosphorylation of MEK/ERK pathway and the downstream c-Myc/PD-L1 axis in mice with breast cancer, which provides an experimental basis for the adjuvant targeting therapy of breast cancer with moxibustion.

Additionally, c-Myc enhances the transcriptional expression of TKT, creating a positive feedback loop between TKT and c-Myc. These findings identify a TKT/c-Myc positive feedback loop that underlies TACE resistance and HCC progression, nominating TKT as a biomarker of refractoriness and a therapeutic target to improve locoregional treatment outcomes.